Revive Therapeutics Ltd. is a Canada-based clinical-stage company. The Company is focused on commercializing treatments for gout and orphan drug indications, such as cystinuria, Wilson disease and Rett syndrome. The Company's business model focuses on finding new uses of old drugs through drug repurposing with the objective of finding an appropriate partner or partners to bring the new use drug to the marketplace. The Company is focused on the development of its candidate, REV-002, which is bucillamine for treatment of gout. Other candidates in the Company's product pipeline include REV-001, which is tianeptine for treatment of opioid-induced respiratory depression in a perioperative setting; REV-003, which is tianeptine for treatment of Rett Syndrome; REV-004, which is bucillamine for the treatment of cystinuria, and REV-005, which is bucillamine for the treatment of Wilson disease.